Vyome Holdings (HIND) Enterprise Value (2025 - 2026)

Vyome Holdings (HIND) posted Enterprise Value of $8.5 million for Q2 2026, up 11.51% on a QoQ basis from $7.6 million in Q1 2026.

Analysis

Vyome Holdings (HIND) Enterprise Value (2025 - 2026) Analysis & Trends

Vyome Holdings has reported Enterprise Value for 2 years, with the latest figure at $8.5 million in Q2 2026.

On a quarterly basis, Enterprise Value changed N/A year-over-year to $8.5 million in Q2 2026; TTM through Jun 2026 was $8.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $3.8 million, changed N/A from the prior year.
Enterprise Value was $8.5 million for Q2 2026 at Vyome Holdings, up from $7.6 million in the prior quarter.
The five-year high for Enterprise Value was $10.0 million in Q3 2025, with the low at $3.8 million in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	211.73 Bn	197.74 Bn	7.24 Bn
2	Gilead Sciences	180.92 Bn	177.74 Bn	6.22 Bn
3	Vertex Pharmaceuticals	132.16 Bn	124.30 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	82.89 Bn	74.90 Bn	3.93 Bn
5	Argenx Se	61.41 Bn	56.23 Bn	1.37 Bn
6	Moderna	53.99 Bn	48.85 Bn	52.00 Mn
7	Alnylam Pharmaceuticals	34.48 Bn	31.18 Bn	992.69 Mn
8	Biogen	31.15 Bn	29.86 Bn	1.96 Bn
9	Roivant Sciences	30.05 Bn	30.05 Bn	1.16 Mn
10	Vyome Holdings	14.46 Mn	6.57 Mn	11,658.00

Historic Data

Download Data